Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore

(Released 10 May 2017) Gaithersburg, MD – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon-cutting ceremony led by Dr. Rick Bright, director of the Biomedical Advanced Research and Development Authority (BARDA), and Daniel J. Abdun-Nabi, Emergent’s president and chief executive officer, to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore. The facility is one of three centers designated by the U.S. Department of Health and Human Services to provide advanced development and manufacturing of medical countermeasures to support the U.S. government’s national security and public health emergency needs.

“With the expansion of our Bayview campus, Emergent is pleased to directly support BARDA’s vision of enhancing the nation’s capability to respond quickly to both known and emerging public health threats,” said Abdun-Nabi. “This milestone strengthens our manufacturing infrastructure, which is one of our core competencies, and symbolizes Emergent’s commitment to the City of Baltimore and the State of Maryland, where we are proud to meaningfully contribute to economic activity and job growth.”  

“The Centers for Innovation in Advanced Development and Manufacturing were designed as public-private partnerships to provide greater speed, flexibility, and domestic capacity to produce medical countermeasures to address public health emergencies,” said Bright. “The work that we do in BARDA – and that we do together with industry partners at our CIADMs – is critical to protecting Americans’ health in emergencies and is fundamental to our nation’s security.”

Emergent has doubled the Bayview facility’s footprint to 112,000 square feet with investments to the original 56,000-square-foot facility purchased by the company in 2009. The facility, comprised of laboratory, manufacturing and office space, offers flexible manufacturing of drug substance from microbial, cell culture or viral production platforms and is equipped with disposable manufacturing technology to enable Emergent to meet the government’s domestic preparedness priorities on a cost-effective, reliable and sustainable basis. The new suite within the expanded facility is expected to come online with cGMP production capabilities in late 2018.

Since its inception, the Emergent CIADM has been awarded four task orders by BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. Emergent also successfully manufactured some of its product candidates at the CIADM and an Ebola vaccine candidate as part of a third-party collaboration.

Emergent employs approximately 1,200 employees worldwide. More than 500 employees are located across four sites in Maryland, including its Bayview Campus, Camden manufacturing facility, and corporate headquarters and product development site in Gaithersburg.

BARDA contract HHSO100201200004I, awarded to Emergent in June 2012 to establish a CIADM, consists of an eight-year base period of performance valued at approximately $220 million (cost-shared between the government and Emergent) and up to 17 additional one-year option periods. BARDA is a division within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

Quotes from Government Officials:

Sen. Chris Van Hollen (D-Md.)
“Maryland’s biopharmaceutical industry continues to grow and create good-paying jobs. Emergent's new Bayview facility is an exciting addition to their statewide footprint, and people across the nation could benefit from their vaccines and therapeutic treatments like those for anthrax and Zika. A successful biopharmaceutical industry requires a coordinated strategy to both expand job opportunities and ensure our next generation of workers has the skills needed to fill these jobs. I will continue to work on the federal level to help the industry grow in Maryland so the lifesaving innovations made in this sector also provide an economic boost to our state.”

Rep. John Sarbanes (D-3rd District)
“Maryland is home to a vibrant biotechnology industry that supports thousands of good-paying jobs. The expansion of Emergent BioSolutions’ Bayview facility in Baltimore will help ensure that Maryland remains a leader in biotechnology innovation and will help boost our state’s economy for many years to come.”

Rep. Andy Harris (R-1st District)
“I congratulate Emergent BioSolutions today on the expansion of their Center for Innovation in Advanced Development and Manufacturing that fulfils such a critically important component of America’s countermeasure development and biosecurity enterprise.”

Rep. C.A. Dutch Ruppersberger (D-2nd District)
“Emergent BioSolutions’ expansion was a public-private investment in the welfare of all Americans through the development of vaccines and treatments for diseases from the flu to Ebola. For us Baltimoreans, it’s also exciting because it means more high-quality manufacturing jobs in the cutting-edge biosciences sector. I congratulate Emergent and thank them for their commitment to Maryland and our great city.”

Maryland Governor Larry Hogan 
“Emergent BioSolutions plays a critical role in addressing many of our nation’s emerging public health threats and we are proud they are continuing to do that important work right here in Maryland. Doubling the size of its Bayview facility and adding new jobs to meet its increased capabilities is further confirmation that Maryland offers an outstanding environment for life sciences companies to thrive.”

Baltimore Mayor Catherine E. Pugh 
“It’s exciting to witness the continued growth of Emergent BioSolutions in Maryland and Baltimore City. I am encouraged by so many businesses investing and expanding in Baltimore. Not only does Emergent make meaningful products, which improve public health, the company is bringing and keeping manufacturing jobs in the city – jobs that provide family-sustaining wages.”

Baltimore City Council President Bernard C. “Jack” Young
“I am extremely pleased to see Emergent expanding its manufacturing capabilities in Maryland. They are at the forefront of innovation, and represent everything we want in a Baltimore area company. Emergent also continues to emphasize local hiring, which I have fought hard to promote so we can increase job opportunities and put our city to work. I commend Emergent for its commitment to our city schools where they teach students about manufacturing and expose them to potential career paths in science. I am confident Emergent will continue to be an asset to Baltimore.”

About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.

Robert G. Burrows
Vice President, Investor Relations
Phone: 240-631-3280
Email: BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
Phone: 240-631-3281
Email: KiefferL@ebsi.com

Released by Emergent BioSolutions. Click here for source.